MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific AdvisorGlobeNewsWire • 02/27/24
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung CancerGlobeNewsWire • 02/22/24
MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung CancerBusiness Wire • 02/07/24
MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting CompoundsBusiness Wire • 01/24/24
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024Business Wire • 01/17/24
MAIA Biotechnology: Significantly Undervalued With Novel Mechanism And Impressive Early DataSeeking Alpha • 01/04/24
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung CancerBusiness Wire • 12/19/23
Bears are Losing Control Over MAIA Biotechnology, Inc. (MAIA), Here's Why It's a 'Buy' NowZacks Investment Research • 12/01/23
MAIA Biotechnology Announces Closing of $4 Million Registered Direct OfferingBusiness Wire • 11/17/23
MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain CancerAccesswire • 11/17/23
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for GlioblastomaBusiness Wire • 11/10/23
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIOBusiness Wire • 11/07/23
MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung CancerAccesswire • 10/31/23
MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIOBusiness Wire • 10/30/23
MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 TrialBusiness Wire • 10/24/23
MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023Business Wire • 10/19/23
MAIA Biotechnology's THIO Emerges As Potential Breakthrough In Pediatric Brain Cancer TherapyAccesswire • 10/17/23
MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society's International Biochemistry Congress 2023Business Wire • 10/17/23
MAIA Biotechnology Reveals New Data Showing THIO's Potent Anticancer Activity in Aggressive Pediatric Brain CancerBusiness Wire • 10/12/23
MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed PatientsBusiness Wire • 10/10/23
MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung CancerBusiness Wire • 10/03/23